1.The Effect of Novel Phosphodiesterase 4 Inhibitor ZL-n-91 to the Proliferation of Leukemia Cells.
Ping MAO ; Zheng-Gang ZHAO ; Lan WANG ; Yu-Yu LI ; Mei-Rong LI ; Su-Jin ZHOU ; Xin-Dan ZHANG ; Yu WANG ; Fang-Hong LI ; Zi-Jian ZHAO
Journal of Experimental Hematology 2021;29(5):1387-1393
OBJECTIVE:
To investigate the inhibitory effects of novel phosphodiesterase 4 inhibitor ZL-n-91 to the proliferation of leukemia cells L1210 and K562.
METHODS:
CCK-8 method was used to detect the effect of ZL-n-91 to the proliferation of L1210 and K562 cells, and the proliferation rate, IC
RESULTS:
ZL-n-91 showed a significant inhibitory effect to the proliferation of leukemia cells L1210 and K562 in a dose-dependent manner (P<0.001). After treated by ZL-n-91, the leukemia cells L1210 and K562 in the S-phase in cell cycle decreased significantly compared with those in control group (P<0.01). The apoptosis of leukemia cells L1210 and K562 could be induced by ZL-n-91 (P<0.001), and the expression level of apoptosis related protein BAX significantly increased. In the animal experiment, the result showed that ZL-n-91 could significantly inhibit the growth of subcutaneously transplantation tumor (P<0.05).
CONCLUSION
The novel phosphodiesterase 4 inhibitor ZL-n-91 can effectively inhibit the proliferation of leukemia cells L1210 and K562, which has the potential of anti-leukemia drug development.
Animals
;
Cell Proliferation
;
Humans
;
K562 Cells
;
Leukemia
;
Mice
;
Mice, Nude
;
Phosphodiesterase 4 Inhibitors/pharmacology*
2.Progress in PDE4 targeted therapy for inflammatory diseases.
Journal of Zhejiang University. Medical sciences 2014;43(3):353-358
cAMP-specific phosphodiesterase type 4 (PDE4) is one of the hot targets for treatment of inflammatory diseases. PDE4 inhibitors can suppress inflammation by increasing the concentration of cAMP in inflammatory cells. The efficacy and safety evaluations of several PDE4 inhibitors are currently carried on in clinical trials, for example GSK256066 in asthma, roflumilast and GSK256066 in chronic obstructive pulmonary disease, tetomilast in inflammatory bowel disease, and apremilast in dermatitis and arthritis etc. This article reviews the recent progress on PDE4-targeted therapy for inflammatory diseases.
Aminopyridines
;
pharmacology
;
Aminoquinolines
;
pharmacology
;
Arthritis
;
drug therapy
;
Asthma
;
drug therapy
;
Benzamides
;
pharmacology
;
Cyclopropanes
;
pharmacology
;
Dermatitis
;
drug therapy
;
Humans
;
Inflammation
;
drug therapy
;
Inflammatory Bowel Diseases
;
drug therapy
;
Phosphodiesterase 4 Inhibitors
;
pharmacology
;
Pulmonary Disease, Chronic Obstructive
;
drug therapy
;
Sulfones
;
pharmacology
;
Thalidomide
;
analogs & derivatives
;
pharmacology
;
Thiazoles
;
pharmacology